Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy as First-Line Treatment in Participants With PD-L1 High (≥50% of Tumor Cells Expressing PD-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (BE6A LUNG-02)

Next Previous
Trial Profile

An Open-Label, Randomized, Controlled Phase 3 Study of Sigvotatug Vedotin in Combination With Pembrolizumab Compared With Pembrolizumab Monotherapy as First-Line Treatment in Participants With PD-L1 High (≥50% of Tumor Cells Expressing PD-L1), Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer (BE6A LUNG-02)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sigvotatug vedotin (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms Be6A Lung-02
  • Sponsors Pfizer

Most Recent Events

  • 15 Sep 2025 Planned number of patients changed from 722 to 737.
  • 18 Aug 2025 Planned number of patients changed from 714 to 722.
  • 14 May 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top